ValueCentric names Boardman VP data services and analytics
ORCHARD PARK, N.Y. ValueCentric announced Monday that Chris Boardman joined its management team as VP data services and analytics.
The company is an on-demand data management and performance analytics to the pharmaceutical industry. Boardman, who has more than 20 years of experience in the healthcare consulting profession, will lead efforts to further expand ValueCentric’s offerings in prescription level data services through its ValueTrak platform.
Dave Janca, founder and CEO of ValueCentic said, “Chris Boardman’s expertise with prescription data position’s him to further strengthen and expand our growing data services and our ValueTrak platform. He’ll play an instrumental role in our growth strategy as we bring to market more unique data streams delivered in real-time through our integrated analytic solution. Chris’ track record will help to ensure that our customers remain at the forefront of industry change with transformational data management and performance analytic service \options.”
Pfizer may buy Ratiopharm
NEW YORK It appears that Pfizer has changed its mind a second time about buying Ratiopharm.
According to published reports, Pfizer has renewed its offer for the German generic drug maker, for $4 billion. That pits the world’s largest drug maker against generic drug makers Teva Pharmaceutical Industries and Actavis.
Pfizer has been on a hunt for opportunities lately, most notably with its acquisition of Wyeth, as it faces patent expirations on such high-selling drugs as the cholesterol medication Lipitor (atorvastatin).
Walgreens completes acquisition of SpecialtyScripts
DEERFIELD, Ill. Walgreens has completed its acquisition of prescription files from Cardinal Health subsidiary SpecialtyScripts, based in Fall River, Mass., Walgreens announced Wednesday.
Founded in 2002, SpecialtyScripts niche is in providing specialty pharmacy services for such chronic illnesses and complex diseases as hepatitis C, psoriasis, rheumatoid arthritis and oral oncology.
Walgreens said the acquisition would allow Walgreens Specialty Pharmacy to scale the operations of its existing locations. Financial terms of the deal were not disclosed.
“We’re excited about our acquisition of SpecialtyScripts and see it as an opportunity to grow our specialty pharmacy business through additional preferred payer agreements,” Walgreens Specialty Pharmacy EVP and Walgreens divisional VP Michael Nameth said in a statement. “It’s a good fit for us because SpecialtyScripts has a similar client base, and we share a commitment to providing patients and customers with quality care and exceptional service.”